
UK-369003
CAS No. 334827-98-4
UK-369003( Gisadenafil besylate )
Catalog No. M14135 CAS No. 334827-98-4
UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 224 | Get Quote |
![]() ![]() |
50MG | 799 | Get Quote |
![]() ![]() |
100MG | 1206 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameUK-369003
-
NoteResearch use only, not for human use.
-
Brief DescriptionUK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.
-
DescriptionUK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM, displays 117-fold selectivity over PDE6; demonstrates efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).COPD Phase 2 Discontinued.
-
In VitroSince some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity.
-
In VivoGisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. Animal Model:Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia Dosage:2 mg/kg Administration:Intraperitoneal injection; for 2 hours Result:Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia.
-
SynonymsGisadenafil besylate
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number334827-98-4
-
Formula Weight677.79
-
Molecular FormulaC23H33N7O5S.C6H6O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (147.54 mM)
-
SMILESCCC1=C2C(=NN1CCOC)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC.C1=CC=C(C=C1)S(=O)(=O)O
-
Chemical Name5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rawson DJ, et al. Bioorg Med Chem. 2012 Jan 1;20(1):498-509.
2. Martínez-Salamanca JI, et al. Eur Urol. 2011 Sep;60(3):527-35.
3. Watson KJ, et al. Drug Metab Dispos. 2011 Jul;39(7):1203-13.
molnova catalog



related products
-
WAY-313170
WAY-313170 Inhibits hedgehog signaling and phosphodiesterase.
-
Resibufogenin
Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system.
-
RPL-554
RPL-554 (LS-193855, RPL554)?is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.